Combined RASSF1A and RASSF2A Promoter Methylation Analysis as Diagnostic Biomarker for Bladder Cancer
Figure 4
RASSF1A and RASSF2A methylation profiles in different T stage. RASSF1A was only 6% (1/16) in normal adjacent tissues, but percentage of tumor samples with methylated RASSF1A genes had a range of 55% −83% from T1 to T4 stage. The RASSF2A promoter had a low level (0–18%) at different T stages.
